Fibrinolysis in patients with the 1691 G→A mutation in factor V gene and history of deep vein thrombosis

Fibrinolysis and Proteolysis

Volumn 11, Issue 4, 1997, Pages 201-207

  Stegnar, M ^a,b   Peternel, P ^a   Uhrin, P ^a   Cvelbar Marinko, T ^a   Gorsic Tomazic K ^a   Binder, B R ^a  

^a UNIVERSITY MEDICAL CENTRE LJUBLJANA   (Slovenia)

^b UNIVERSITY OF VIENNA   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

ACTIVATED PROTEIN C; BLOOD CLOTTING FACTOR 5; PLASMINOGEN ACTIVATOR INHIBITOR 1; PROTEIN S; TISSUE PLASMINOGEN ACTIVATOR;

ADULT; ARTICLE; BLOOD CLOTTING; DEEP VEIN THROMBOSIS; DISEASE SEVERITY; FEMALE; FIBRINOLYSIS; GENE MUTATION; HEMATOLOGICAL PARAMETERS; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RECURRENT DISEASE; RISK FACTOR; VEIN THROMBOSIS;

EID: 0030668260     PISSN: 13690191     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0268-9499(97)80051-3     Document Type: Article

References (32)

1. Dahlbäck B, Carlsson M, Svensson PJ. Familial thrombophilia due to a previously unrecognized mechanism characterized by a poor anticoagulant response to activated protein C: prediction of a cofactor to activated protein C. Proc Natl Acad Sei USA 1993; 90: 1004-8.
2. Koster T, Rosendaal FR, de Ronde H, Briët E, Vandenbroucke JP, Bertina RM. Venous thrombosis due to poor anticoagulant response to activated protein C: Leiden thrombophilia study. Lancet 1993; 342: 1503-6.
3. Svensson PJ, Dahlbäck B. Resistance to activated protein C as a basis for venous thrombosis. N EngI J Med 1994; 330:517-21.
4. Griffin JH, Evatt B, Wideman C, Fernândez JA. Anticoagulant protein C pathway defective in majority of thrombophilic patients. Blood 1993; 82: 1989-93.
5. Bertina RM, Koeleman BPC, Koster T, Rosendaal FR, Dirven RJ, de Ronde H, van der Velden PA, Reitsma PH. Mutation in blood coagulation factor V associated with resistance to activated protein C. Nature 1994; 369: 64-7.
6. Dahlbäck B. New molecular insights into the genetics of thrombophilia. Resistance to activated protein C caused by Arg506 to Gin mutation in factor V as a pathogenetic risk factor for venous thrombosis. Thromb Haemost 1995; 74: 139-48.
7. Koeleman BPC, Reitsma PH, Allart CF, Bertina RM. Activated protein C resistance as an additional factor for thrombosis in protein C-deficient families. Blood 1994; 84: 1031-5.
8. Gandrille S, Greengard JS, Alhenc-Gelas M, Juhan-Vague I, Abgrall JF, Jude B, Griffin JH, Aiach M, the French Network on the behalf of INSERM. Incidence of activated protein C resistance caused by the ARG 506 GLN mutation in factor V in 113 unrelated symptomatic protein C-deficient patients. Blood 1995; 86:219-24.
9. Zöller B, Berntsdotter A, Garcia de Frutos P, Dahlbäck B. Resistance to activated protein C as an additional genetic risk factor in hereditary deficiency of protein S. Blood 1995; 85: 3518-23.
10. Koeleman BPC, van Rumpt D, Hamulyâk K, Reitsma PH, Bertina RM. Factor V Leiden: An additional risk factor for thrombosis in protein S deficient families? Thromb Haemost 1995; 74: 580-3.
11. Vandenbroucke JP, Koster T, Briet E, Reitsma PH, Bertina RM, Rosendaal FR. Increased risk of venous thrombosis in oral-contraceptive users who are carriers of factor V Leiden mutation. Lancet 1994; 344: 1453-7.
12. Hellgren M, Svensson PJ, Dahlbäck B. Resistance to activated protein C as a basis for venous thromboembolism associated with pregnancy and oral contraceptives. Am J Obstet Gynecol 1995; 173:210-3.
13. De Stefano V, Mastrangelo S, Paciaroni K, Ireland H, Lane DA, Scirpa P, Bizzi B, Leone G. Thrombotic risk during pregnancy and puerperium in women with APC-resistance - effective subcutaneous heparin prophylaxis in a pregnant patient. Thromb Haemost 1995; 74: 793-4.
14. Isacson S, Nilsson IM. Defective fibrinolysis in blood and vein walls in recurrent 'idiopathic' venous thrombosis. Acta Chir Scand 1972; 138: 313-9.
15. Nilsson IM, Ljungner H, Tengborn L. Two different mechanisms in patients with venous thrombosis and defective fibrinolysis: low concentration of plasminogen activator or increased concentration of plasminogen activator inhibitor. Br Med J 1985; 290: 1453-6.
16. Jorgensen M, Bonnevie-Nielsen V. Increased concentration of the fast-acting plasminogen activator inhibitor in plasma associated with familial venous thrombosis. Br J Haematol 1987; 65: 175-80.
17. Juhan-Vague I, Valadier J, Alessi MC, Aillaud MF, Ansaldi J, Philip-Joel C, Holvoet P, Serradimigni A, Collen D. Deficient tPA release and elevated PA inhibitor levels in patients with spontaneous or recurrent deep venous thrombosis. Thromb Haemost 1987; 57: 67-72.
18. Malm J, Laurell M, Nilsson IM, Dahlbäck B. Thromboembolic disease - critical evaluation of laboratory investigation. Thromb Haemost 1992; 68: 7-13.
19. Gram J, Sidelmann J, Jespersen J. Does low protein concentration of tissue-type plasminogen activator predict a low risk of spontaneous deep vein thrombosis? Thromb Haemost 1995; 74: 718-21.
20. Schulman S, Wiman B, the Duration of Anticoagulation (DURAC) Trial Study Group. The significance of hypofibrinolysis for the risk of recurrence of venous thromboembolism. Thromb Haemost 1996; 75: 607-11.
21. Ridker PM, Vaughan DE, Stampfer MJ, Manson JAE, Shen C, Newcomer LM, Goldhaber SZ, Hennekens CH. Baseline fibrinolytic state and the risk of future venous thrombosis. A prospective study of endogenous tissue-type plasminogen activator and plasminogen activator inhibitor. Circulation 1992; 85: 1822-7.
22. Stegnar M, Peternel P, Keber D, Vene N. Poor fibrinolytic response to venous occlusion by different criteria in patients with deep vein thrombosis. Thromb Res 1991; 64: 445-53.
23. Stegnar M, Mavri A. Reproducibility of fibrinolytic response to venous occlusion in healthy subjects. Thromb Haemost 1995; 73: 453-7.
24. Wiman B, Ljungberg B, Chmielewska J, Urden G, Blombäck M, Johnsson H. The role of the fibrinolytic system in deep vein thrombosis. J Lab Clin Med 1985; 105: 265-70.
25. Korninger C, Lechner K, Niessner H, Gössinger H, Kundi M. Impaired fibrinolytic capacity prepisposes for recurrence of venous thrombosis. Thromb Haemost 1984; 52: 127-30.
26. Lackner H, Merskey C. Variations in fibrinolytic activity after acute myocardial infarction and after administration of oral anticoagulant drugs and intravenous heparin. Br J Haematol 1960; 6:402.
27. Grulich-Henn J, Loechelt K, Speiser W, Müller-Bergbaus G. Increased tissue-plasminogen activator (t-PA) levels in patients under oral anticoagulant therapy. Blut 1989; 58: 39-43.
28. Grimaudo V, Bachmann F, Kauert J, Christe M-A, Kruithof EKO. Hypofibrinolysis in patients with a history of idiopathic deep vein thrombosis and/or pulmonary embolism. Thromb Haemost 1992; 67: 397-401.
29. De Ronde H, Bertina RM, Laboratory diagnosis of APCresistance: a critical evaluation of the test and the development of diagnostic criteria. Thromb Haemost 1994; 72: 880-6.
30. Leroy-Matheron C, Lèvent M, Pignon J-M, Mendonçac, Gouault-Heilmann M. The 1691 G->A mutation in the factor V gene: relationship to activated protein C (APC) resistance and thrombosis in 65 patients. Thromb Haemost 1996; 75: 4-10.
31. Rees DC, Cox M, Clegg JB. World distribution of factor V Leiden. Lancet 1995; 346: 1133-4.
32. Zöller B, Svensson PJ, He X, Dahlbäck B. Identification of the same factor V gene mutation in 47 out of 50 thrombosis-prone families with inherited resistance to activated protein C. J Clin Invest 1994; 94: 2521-4.